INNOVATE (VATE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 10, 2026.
Voting matters and shareholder proposals
Election of four directors: Avram A. Glazer, Warren H. Gfeller, Brian S. Goldstein, and Amy M. Wilkinson, all recommended by the board.
Advisory vote to approve named executive officer compensation (Say on Pay Vote).
Proposal to amend the 2014 Omnibus Equity Award Plan to increase available shares for issuance.
Ratification of BDO USA, P.C. as independent auditor for fiscal year ending December 31, 2026.
Consideration of any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Latest events from INNOVATE
- Major asset sales will eliminate most revenue, with proceeds used for debt repayment, not shareholders.VATE
Registration filing - Q2 2026 revenue jumped 74.2% to $421.6M, with net income of $10.4M and major asset sales underway.VATE
Q2 2026 - All proposals passed, directors elected, and no questions raised during the Q&A session.VATE
AGM 2026 - Revenue up 33% to $364.8M, net loss narrowed, but debt maturities pose going concern risk.VATE
Q1 2026 - Board recommends FOR all proposals, with focus on growth, governance, and executive alignment.VATE
Proxy filing - Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 2025 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 2024 - Q2 net income rose to $14.4M as margins improved and Life Sciences posted record sales.VATE
Q2 2024 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 2024